Brief
Medtech Investment Firm Accelmed Backs Reflux Therapy Company EndoGastric
EndoGastric develops incisionless procedural therapy for gastroesophageal reflux disease
15:2728.05.19
Israel-based medtech investment firm Accelmed Growth Partners has joined a funding round of about $45 million for Redmond, Washington-based medical device company EndoGastric Solutions Inc., the two announced Tuesday. Of the sum, Accelmed invested $15 millions. Other participants in the round include Canaan Partners, Chicago Growth Partners, and De Novo Ventures.
Accelmed Co-Founder and Managing Partner Uri Geiger. Photo: PR
Founded in 2003, EndoGastric develops incisionless procedural therapy for gastroesophageal reflux disease.
Based in Israeli central town Herzliya, with additional offices in New York, Accelmed has $350 million in assets under management. Founded in 2009 by Israeli businessmen Mori Arkin and Uri Geiger, the firm invests in small and mid-cap private and public companies in the digital health industry.
Accelmed Co-Founder and Managing Partner Uri Geiger. Photo: PR 